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Abstract
Background: The cell adhesion molecule L1-like (CHL1 or CALL) gene is located on chromosome 3p26.3, and it is
highly expressed in the central and peripheral nervous systems. The protein encoded by this gene is a member of
the L1 family of neural cell adhesion molecules, and it plays a role in nervous system development and synaptic
plasticity. Moreover, studies of mice have revealed that CHL1 is a prime candidate gene for a dosage-sensitive
autosomal form of mental retardation. To date, four patients with a microdeletion and two with a microduplication
of 3p26.3 encompassing only the CHL1 gene have been reported in literature.
Case presentation: In the present study, we have described a 16-month-old boy with autism spectrum disorder
(ASD), developmental delay and minor dysmorphic facial features. This is the first report of a duplication of 3p26.3
including only the CHL1 gene in an ASD patient, and this duplication is the smallest reported to date in this gene.
We also reviewed CHL1 gene mutation cases and examined whether this gene has an important role in cognitive
function.
Conclusions: We conclude that both CHL1 deletions and duplications are likely responsible for the patient’s
impaired cognitive function, and CHL1 may be an intriguing ASD candidate gene.
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Background
Autism spectrum disorder (ASD) is a group of neurode-
velopmental disorders characterized by impairments in
social interaction and verbal and non-verbal communi-
cation, as well as restricted and repetitive behaviors. In
the United States, the most recent estimate as of 2010 is
that 1 in every 68 children have some form of ASD [1].
Genetic factors play a prominent role in ASD pathogen-
esis. According to recent studies, the majority of copy
number variations (CNVs) affect only one copy of a gene
(which can be either deleted or duplicated), suggesting
that abnormal gene dosage or expression might play a
key role in susceptibility to ASD [2, 3].
The cell adhesion molecule L1-like (CHL1 or CALL)
gene is located on chromosome 3p26.3, and it is highly
expressed in the central and peripheral nervous systems.
The protein encoded by this gene is a member of the L1
family of neural cell adhesion molecules, and it plays a
role in nervous system development and synaptic plasti-
city [4, 5]. To date, four patients with a microdeletion of
3p26.3 including only the CHL1 gene have been re-
ported in the literature. All of these patients presented
with cognitive impairment characterized by learning and
language difficulties [6–8]. Frints et al. have studied
CHL1 expression in the hippocampi of CHL1+/− mice and
have found that it is half of that observed in wild-type lit-
termates, indicating the existence of a gene dosage effect.
This group has suggested that a 50 % reduction in CHL1
expression in the developing brain results in cognitive def-
icits [4]. However, less is known about the reciprocal
microduplication of this gene.
To the best of our knowledge, only two families with a
microduplication of 3p26.3 including only the CHL1
gene have been described to date, including one intellec-
tually disabled girl with epilepsy and one male patient with
developmental delay (DD), symptoms of hyperactivity, a
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short attention span and speech delay. The duplications
detected by array comparative genomic hybridization
(CGH) were 1.07 and 0.85 Mb in size, respectively [4].
Here, we describe a male patient with ASD and DD for
whom array CGH analysis revealed the presence of a
0.69 Mb duplication of 3p26.3. The duplication was trans-
mitted from his normal mother and included only the
CHL1 gene.
Tassano et al. have reviewed CHL1 gene deletion cases.
In contrast, here, we review the phenotypic and molecu-
lar features of CHL1 gene duplication cases and assess
whether this gene plays an important role in cognitive
function.
Case presentation
The 16-month-old patient is the first child of healthy,
non-consanguineous parents. He has a normal male
karyotype and no family history of developmental or
neuropsychiatric disorders, except for schizophrenia in
his maternal grandmother. This child was born at term
by caesarean section with hypoxia, and his Apgar scores
were 6 and 9 at 1 and 5 min, respectively. At birth, his
weight was 3450 g (50–80th percentile), and his length
and head circumference were not reported. He has suffered
from a feeding disorder from birth and still continues to
exhibit eating refusal and vomiting problems. He had gen-
eral DD and started walking at 15 months of age. His
speech was delayed, with first babbling at approximately
8 months old, and he still cannot consciously generate
words. He appeared to exhibit gaze avoidance and did not
respond when his name was called. He preferred to look at
traffic lights and exit signs. He continuously knocked the
desk in the examination room with his hands or other ob-
jects. At 16 months of age, physical examination revealed
the following findings: a weight of 9.95 kg (10–20th
percentile), a height of 80.1 cm (20–50th percentile),
and minor dysmorphic facial features, including mild
hypertelorism, a short mandible and a protuberant fore-
head (Fig. 1). MRI scanning of his brain was unremarkable,
and the EEG and fragile X screening results were also
normal.
Cognitive/developmental evaluation using the Bayley
Scales of Infant Development-2 showed that his cogni-
tive and language skills, as well as his motor skills, were
well behind for his age (MDI < 50; and PDI = 66). The
Autism Diagnostic Observation Schedule (ADOS)-Tod-
dler Module was used for autism screening. The results
of this test revealed that the patient had a social affect
score of 20, a restricted and repetitive behavior score of
5 and an overall total score of 25, indicating a likely
diagnosis of moderate-to-severe ASD. His was finally diag-
nosed with ASD according to the Diagnostic and Statis-
tical Manual of Mental Disorders, Fifth Edition (DSM-V)
criteria.
His mother was a 37-year-old female who had consid-
ered herself healthy throughout her life. Her childhood
had been unremarkable, and she did not show any DD,
not even when she was young. She scored in the normal
range on the Broad Autism Phenotype Questionnaire
(BAPQ) [9] and Symptom Checklist-90 (SCL-90) [10].
The final patient karyotype was 46, XY, inv(9)(p12q13).
Array CGH revealed a 687 kb microduplication of
chromosome 3p26.3 (380,685–1,067,787) that only involved
the CHL1 gene. This duplication started at exon 5 and con-
tinued to the end of the gene. qPCR was performed, and
the results verified that the gene was duplicated in the
patient and that it was inherited from his normal mother.
Because the duplication included the region from exon 5 to
the end of the gene, exon 4 had a normal copy number.
Exons 12 and 26 were duplicated (Fig. 2).
Fig. 1 Face of the patient showing mild facial dysmorphic features and his family pedigree. Standard pedigree symbols are used;
dup, duplication
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Discussion
In the present study, we describe a 16-month-old boy
with ASD, DD and minor dysmorphic facial features.
This is the first report of a duplication of 3p26.3 includ-
ing only the CHL1 gene in an ASD patient, and the du-
plication described here is the smallest reported to date
involving this gene.
The CHL1 gene encodes a neural cell adhesion protein
that belongs to the immunoglobulin superfamily. It is lo-
cated on chromosome 3p26.3 and is highly expressed in
the central and peripheral nervous systems. It plays a
role in regulating neuronal migration and neurite over-
growth in the developing brain. Furthermore, CHL1 was
expressed in the dorsal thalamus and on fibers along the
thalamocortical projection in the ventral telencephalon
and cortex. It could also play a vital role in thalamocortical
connectivity [11]. In a study of CHL1-deficient (CHL1−/−)
mice, researchers found that GABAergic synaptic con-
nectivity due to the gene mutation resulted in en-
hanced synaptic elimination, leading to microgliosis,
increased expression of interleukin-6 and the loss of
parvalbumin-expressing interneurons and ultimately
impaired synaptic plasticity [12]. Moreover, studies of
mice have found that CHL1 is a dosage-sensitive gene
[4, 5, 12]. In humans, mutation of the CHL1 gene has
been associated with distal 3p deletion syndrome
(OMIM 613792). This syndrome is a rare contiguous
genetic disorder involving deletion of chromosome
3p25-p26 and is characterized by DDs, low birth
weight, growth retardation, micro- and brachycephaly,
ptosis, a long philtrum, micrognathia, and low-set ears
[13, 14]. The CHL1 gene is the most telomeric gene
known on 3p, and it has been suggested to be candi-
date gene for cognitive impairment in 3p syndrome
patients [4, 15].
To date, four familial cases presenting with a heterozy-
gous deletion of chromosome 3p26.3 including only the
CHL1 gene have been reported. First, a 6-year-old boy
was reported who presented with microcephaly, short
stature, mild mental retardation, learning and language
delays, and strabismus. His gene deletion was transmitted
from his normal mother [6]. Next, two affected siblings
whose deletions were transmitted from their normal father
were reported who presented with microcephaly, mild
mental retardation, and learning and language difficulties
[7]. Finally a 12-year-old boy was reported who presented
with slow physical development, microcephaly, temper
tantrums, and severe learning disabilities [8]. All subjects
exhibited verbal DD during the first 2 years of life and re-
quired specific therapy. The chromosomal deletions of
3p26.3 present in all four of these patients ranged from
500 Kb to 1.0 Mb in size and included only the CHL1
gene. The deletions were inherited from an apparently
unaffected parent in three cases (data not available in
one case) [6].
In addition, two families have been reported with
microduplication of 3p26.3 including only the CHL1
gene, including one intellectually disabled girl with epi-
lepsy and one male patient with DD, symptoms of hyper-
activity, a short attention span and speech delay. The
phenotypic features and molecular cytogenetic findings
for these two patients, as well as our patient, are shown in
Table 1, and the exact sizes and positions of duplications
of these three cases are shown in Fig. 3. All of the patients
showed DD/intellectual disability and language delay.
Moreover, 6 other similar cases have been reported in the
Decipher Database [https://decipher.sanger.ac.uk]. Among
these 6 cases, one patient exhibited a 731.32 kb duplica-
tion on 3p26.3, containing the entire CHL1 gene, that was
characterized by global DDs, a retinal abnormality, feeding
Fig. 2 Confirmation of CHL1 gene duplication by qPCR. a Results for the ALB reference gene. b Results for the PMP22 reference gene. Fragments
1, 2, and 3 correspond to exons 4, 12 and 26 of the CHL1 gene, respectively. The patient’s father had a normal copy number of the CHL1 gene.
The patient and his mother had a normal copy number of exon 4 but duplication of exons 12 and 26
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difficulties, hypophosphatemia, and scrotal hypoplasia
(n.279556). One patient with a duplication of the entire
CHL1 gene together with another variant on chromosome
7 was characterized by intellectual disability (n.287862).
Another four patients displayed duplication of the first
exon on CHL1 gene and presented intellectual disability
or global DD with or without other phenotypic anomalies
(n.288373, n.289009, n.291512, and n.289754). Because
the information available in the Decipher Database is not
comprehensive, we used the cases that are reported in the
literature for discussion.
Most of the genetic aberrations in these seven patients
were transmitted from a normal parent (three were mater-
nal, two were paternal, one was de novo and no data were
available in one case). These observations are suggestive of
incomplete penetrance. In addition, Chl1+/− mice have
been demonstrated to have a phenotypic spectrum ran-
ging from wild-type to knockout behaviors [4]. Another
possible explanation would be the two-hit model [16].
Other undetected CNVs might exist within the Array
CGH in our patient; these mutations together with the
CHL1 duplication could have caused the abnormalities
in the child but not affected his mother. In addition,
apart from the microarray-analyses, microscopically
visible CNVs (CG-CNVs) might be another possibility
[17]. Moreover, an apparently unaffected parent who
carries the deletion could also have subtle associated
phenotypic features that become evident upon further
clinical evaluation. Other possibilities that may account
for the phenotypic variability among these patients include
differences in genetic background, epigenetic phenomena,
expression or regulatory variation, and the unmasking of
recessive variants located on the other allele [7, 18].
Because the CHL1 gene plays an important role in
regulating neuronal migration and neurite overgrowth in
the developing brain and all seven patients with a CHL1
gene mutation showed DD, we conclude that both CHL1
deletion and duplication are likely to result in impaired
Table 1 Comparison of clinical and molecular findings associated with 3p26.3 duplication, including only the CHL1 gene, between
the present study and previous studies
Subject Present case Shoukier et al. [26] Palumbo et al. [27]
Sex F M F
Age 1 years and 4 months 16 years 2 years and 3 months
Duplication size 0.69 Mb 1.0 Mb 0.85 Mb
Coordinates (hg19) 380,685–1,067,787 48,914–1,054,209 125,931–975,649
Inheritance Maternal Maternal De novo
Pregnancy condition Hypoxia Normal Normal
Delivery Term Term Term
Family history Maternal grandmother with
schizophrenia
No family history No family history
Weight (g) 9.95 kg (10–20th percentile) 57 kg (50th percentile) 15 kg (75–90th percentile)
Height (cm) 80.1 cm (20–50th percentile) 157 cm (25th percentile) 96 cm (90–97th percentile)
Dysmorphic facial
features
Mild hypertelorism, short mandible
and protuberant forehead
No dysmorphic facial features Minor dysmorphic facial features, including
mild hypertelorism, down-slanting, long
palpebral fissures with eversion of lateral
third of lower eyelids, long philtrum, thin
upper lip, and mildly prominent ear lobes
Age at walking 15 months 15 months 12 months
Verbal DD + + +
Seizures - + -
DD/ID + + +
Feeding disorder + - -




Brain MRI Normal Normal Normal
EEG Normal Multifocal sharp waves and sharp
and slow-wave complexes
Normal
Fragile X screening Normal Normal Not reported
M male, F female, + present, − absent, DD developmental delay, ID intellectual disability
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cognitive function in patients. One interpretation of the
gene balance hypothesis is that under- and overexpres-
sion phenotypes are identical, or at least similar, because
both deletions and duplications disrupt an identical mul-
timeric regulatory protein complex (by disruption of the
stoichiometry of protein subunits encoded by the associ-
ated genes) [19]. The relationship between gene dosage
and phenotype is complex. Conrad and Antonarakis have
proposed three alternatives to explain this relationship
that are each characteristic of certain categories of genes.
Based on the reports in the literature, we hypothesize that
the CHL1 gene corresponds with the third alternative,
which involves certain functional gene classes enriched in
transcriptional regulators and signaling molecules that
cause phenotypic changes when both under- and overex-
pressed (haploinsufficiency and pathogenic gene duplica-
tion). Both deletions and duplications are known to occur
within the same chromosomal region in other diseases, for
example, the progressive neurodegenerative disorder Rett
syndrome, which almost exclusively affects females in its
classical form and is due toMECP2 haploinsufficiency. Se-
vere mental retardation and neurological symptoms with
features of Rett syndrome in males can also be caused by
MECP2 duplication [19].
With regard to association of the CHL1 gene with
ASD, Weehi et al. have identified a patient with a 3p26.3
microduplication encompassing part of the CHL1 gene
as well as the CNTN6 gene who presented with motor
and speech DDs and some autistic features. Features in
this patient suggestive of ASD included repetitive activ-
ities, preoccupation with spinning wheels, resistance to
changes in routine, and heightened sensitivity to people
touching his legs. Overall, however, he was not considered
to have ASD [20]. Moghadasi et al. studied the clinical
consequences of a terminal deletion of the short arm of
chromosome 3 in four generations of a family. They de-
tected a 2.9 Mb deletion in the short arm of chromosome
3 in 7/13 family members that contained the candidate
genes CHL1 (OMIM 607416), CNTN4 (OMIM 607280),
and CNTN6 (OMIM 607220). The sister of the index pa-
tient had autism, speech delay, and learning difficulties
[21]. In addition, 3p26.3 microduplication has been re-
ported in a study of CNVs in extended ASD families, but
this aberration did not affect any genes and was located
109 Kb upstream of CHL1 [22]. In the present study, we
report a terminal duplication of 3p26.3 confined to the
CHL1 gene in a boy with ASD. ASD is a group of neuro-
developmental disorders. The etiology and pathogenesis
are still unknown. However, some studies have shown that
the pathogenesis of ASD during early development of the
brain could be relevant to disruptions of serotonin signal-
ing [23]. CHL1 is a modulator of the serotonergic system;
the signal transduction pathways are regulated by consti-
tutive activation of the serotonin 2c (5-HT2c) receptor by
CHL1 [24]. Another study discussed the genome-wide
expression profiling of human lymphoblastoid cell lines
and found that CHL1 is a putative selective serotonin
reuptake inhibitor (SSRI) response biomarker [25]. There-
fore, CHL1 may be an intriguing ASD candidate gene, and
it is likely responsible for the cognitive function impair-
ments of ASD patients with a CHL1 gene mutation.
Conclusion
In the present study, we have described a 16-month-old
boy with ASD, DD and minor dysmorphic facial fea-
tures. This is the first report of a duplication of 3p26.3
confined to the CHL1 gene in an ASD patient, and it is
the smallest reported duplication to date. We have also
Fig. 3 Schematic of the exact sizes and positions of chromosome 3p26.3 showing duplications reported here and other cases reported in the
literature. Schematic of the 3p26.3 region displayed using the UCSC Genome browser [GRCh37/hg19 assembly; http://genome.ucsc.edu]
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reviewed CHL1 gene mutation cases from the literature
and examined whether this gene plays an important role
in cognitive function. Although some clinical symptoms
differ among these patients, such as epilepsy and some
autistic features, all of the subjects showed impaired
cognitive function. Thus, both heterozygous deletions
and duplications of the CHL1 gene may be considered in
the etiology of a new emerging syndrome characterized
by DD and other possible symptoms. Because the
number of reports is limited, the identification of new
cases and further functional studies are required to
confirm the exact function of the CHL1 gene in cognitive
development.
Methods
Array CGH was performed on DNA extracted from the
peripheral blood of the patient using commercially available
arrays (Agilent SurePrint G3 Human CGH Microarray
1 × 1 mol/l, Agilent Santa Clara, California, USA). The
UCSC Genome Browser database (GRCh37/hg19, Feb.
2009) was used as reference of structural variations
identified in healthy human samples.
Real-time quantitative polymerase chain reaction (qPCR)
was performed (SuperReal PreMix Plus, TIANGEN, China)
to verify the presence of the CHL1 microduplication in
this patient and to determine whether it was inherited.
Three pairs of primers were designed using IDT, an online
primer-designing tool (https://www.idtdna.com/Primer-
quest), for exons 4, 12 and 26 of CHL1 gene transcript
variant 1. Relative quantification was performed using a
standard curve against control amplicons of the ALB and
PMP22 genes according to the manufacturer’s instructions
(LightCycler® 480 Instrument, Roche, Germany).
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